The results of the PALLAS study, which evaluated the addition of Palbociclib to adjuvant endocrine therapy in breast cancer, were presented at the ESMOVirtual Congress 2020 on September 20, 2020.The PALLAS study was conducted by the Austrian Breast and Colorectal Cancer Study Group (ABCSG), Austria and the ALLIANCE Foundation Trials group - United States. LACOG participated in the study as part of a collaborative group working in Latin America along with Mexican research centers that made a significant contribution to the study.
GEICAM started this initiative in 2008 with the purpose of presenting an in-depth review of the most relevant milestones presented at congresses and international publications annually. At this annual multidisciplinary meeting, attended by all professional involved with breast cancer, a comprehensive review of the advances made in research, diagnosis and treatment in connection with this disease has been carried out. The main goal of this event is to become a reference for everyone interested in finding out more about the advances made in terms of breast cancer in an independent, comprehensive and critical fashion. Sign up at: https://www.ragmageicam.org/ and participate!
Register for ESMO Highlights Webinar LATAM 2020 here: https://www.esmohighlightswebinar2020.com An excellent opportunity for oncologists in Latin America to update their knowledge, a few days after the ESMO2020 Virtual Congress, based on updated scientific evidence. A Scientific Committee with 8 international experts will meet virtually on 9/26/2020 to discuss the progress presented at the ESMO 2020 Virtual Congress, with selections in Genitourinary, Gastrointestinal, Lung, Melanoma, Head and Neck and Breast Cancer, with the objective of disseminating scientific and clinical advances and their impact on the daily clinical practices in Latin America. The event will take place in a virtual environment, under the leadership of Dr. Antonio C. Buzaid and Dr. Carlos H. Barrios, with simultaneous translation in Portuguese and Spanish.
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
Members of LACOG Breast cancer group have recently published the article “The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)” AMAZONA III/ GBECAM 0115 is a prospective cohort study that evaluated Brazilian patients with newly diagnosed breast cancer from 2016 to 2018. This manuscript depicts a wide and detailed scenario of sociodemographic characteristics of 2,950 breast cancer patients at diagnosis. The patients were from 23 sites in Brazil. The results of the study show that patients with public health coverage were diagnosed with symptomatic disease, at later stages and with more aggressive subtypes of breast cancer when compared to patients with private health coverage. This study brings to light important information that allows us to not only have a better understanding of tumor and patients’ characteristics but also, help to identify gaps within healthcare systems in Brazil. With such knowledge, it’s possible to develop strategies to improve screening and educational programs in the country, especially in the public setting.
2,731 participants from 26 brazilian states and also from other countries, watched, during 4 days, the virtual scientific program. The event was attended by renowned speakers that presented the main studies of ASCO 2020 on different research fields (Genitourinary, Melanoma/Sarcoma, Gastrointestinal, Hematologic, Breast, Gynecological, Lung, Head and Neck and Neuro), in addition to discussing the perspective of clinical practice. We thank all the attendees, speakers, supporters and sponsors for having been a part of this great event. The Best of ASCO 2020 Brazil Edition, organized by LACOG and Ética Institute, is an event officially licensed by ASCO, which organizes the most important oncology congress in the world with a commitment to accelerating progress against cancer, even in the face of a global pandemic.
It is with great pleasure that we inform that GBCP and LACOG Head and Neck Group are now members of the Head and Neck Cancer International Group.
The CURA Project, of which we are supporters, launched a crowdfunding campaign to support research against head and neck cancer. Join us by supporting the campaign to fund 1,000 laboratory tests and contribute to scientific research. We invite you to join together in this great challenge of raising funds to clinical cancer research community. Access The CURA Project website and learn more! Access The Cura Project website
Assistance to cancer patients was dramatically compromised during the covid-19 pandemic, which will result in an increased risk of mortality by approximately 20%.
"A multidisciplinary group with 40 representatives from 35 collaborative groups and medical associations developed a consensus practice recommendations for the continuity of care for patients with head and neck cancer during the pandemic, stressing the importance of not interrupting their treatment, treating patients with established protocols, encouraging distance consultations, and adopting protective measures for patients and staff." - Dr. Prof. Luiz P. Kowalski, Vice-chair LACOG Head and Neck Group and A.C. Camargo Center Oncologist Read more on The Lancet website
Health-related quality of life outcomes in head and neck cancer: results from a prospective, real-world data study with Brazilian patients treated with intensity modulated radiation therapy, conformal and conventional radiation techniques
Marcos Santos, Luís Felipe Oliveira e Silva, Hugo F. Kohler, Otavio Curioni, Ricardo Vilela, Marcel Fang, Carmen Silvia Passos Lima, João Pedro Gomes, Aline Chaves, Bruno Resende, Karine Trindade, Mauricio Collares, Fernando Obs, Janaina Brollo, Ronaldo Cavalieri, Ediane Ferreira, Leandro Brust, Doralina Rabello, Christian Domenge, Luiz Paulo Kowalski - International Journal of Radiation Oncology. September 29, 2020
LBA12 – PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
E.L. Mayer, M.I. Gnant, A. DeMichele, M. Martin, H. Burstein, A. Prat, G. Rubovszky, K.D. Miller, G. Pfeiler, E.P. Winer, N. Zdenkowski, D. Anderson, Z. Nowecki, S. Loibl, H. Fohler, O. Metzger, D. Fumagalli, K. Puyana Theall, C. Fesl, A. Dueck - ESMO Virtual Congress 2020